You are here: Industry Insights > e

News List

Everest Medicines Announces NMPA Full Approval of NEFECON, Broadening Treatment Access for IgA Nephropathy Patients in China ACN Newswire
May 07, 2025
Everest Medicines announced that the supplemental New Drug Application (sNDA) for NEFECON has received full approval from the China National Medical Products Administration (NMPA).
3D Printing in Pharmaceuticals: Transforming Drug Design, Production, and Delivery Saher Haider
May 06, 2025
This article will explore 3D printing's current applications in pharmaceutical production, personalized medicine, and drug discovery, and the future potential of this groundbreaking technology.
Radioconjugates: Targeting for Precision Suzanne Elvidge
May 06, 2025
The development of radioconjugates – targeted molecules designed to carry radionuclides directly to cancerous cells, lowering systemic exposure and increasing the precision of treatment.
Now and Next in Type 2 Diabetes Suzanne Elvidge
May 06, 2025
Type 2 diabetes, the most common form of diabetes, affects more than 800 million adults worldwide.
Pharmacovigilance Regulations and Application: Safeguarding Drug Safety in a Complex Global Environment David Orchard-Webb
May 06, 2025
In a pharmaceutical world characterized by rapid innovation and international marketplaces, safeguarding medication safety beyond commercialization has never been more important.
Sterilization Processes in the Pharmaceutical Industry David Orchard-Webb
May 06, 2025
In this post, we'll look at the numerous sterilization techniques utilized in the pharmaceutical sector, as well as their uses and benefits in terms of product safety and regulatory compliance.
mRNA Technology for Vaccines and Broader Applications Saher Haider
May 06, 2025
Messenger RNA (mRNA) Technology has swiftly made its way to the field of vaccinology, offering a novel approach to immunization that differs fundamentally from traditional mechanisms of vaccination.
InnoCare’s Zurletrectinib Receives Priority Review from China’s NMPA PharmaSources
May 06, 2025
InnoCare Pharma announced today that its new generation pan-TRK inhibitor zurletrectinib (ICP-723) has been granted priority review by the CDE of China NMPA.
Comparison of Improved New Drugs Paths between China and the United States and Analysis of R&D Status in China Kevin
April 28, 2025
This article describes successful practices from the United States 505(b)(2) pathway and analyzes R&D status of China's modified new drugs.
Taking Over the "King of Medicine"? Chinese Enterprises Lead the Development of PD-(L)1/VEGF Bispecific Antibody Antitumor Drug Kevin
April 28, 2025
PD-(L)1 and VEGF (vascular endothelial growth factor) bispecific antibody therapies are considered a key direction for future tumor treatments, attracting increasing global interest due to their unique mechanism of action and promising clinical data.